TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33415379

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) injection (1-mL)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) injection (0.5-mL)
Number of subjects: 2
Study: 32899673

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation (FO and FO + 5-MTHF groups, n = 33)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No Fish Oil (No-FO group, placebo and 5-MTHF groups, n = 24)
Number of subjects: 57
Study: 33883048

Group type: EXPERIMENTAL
Intervention: Breast milk oral care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Physiological saline oral care
Number of subjects: 56
Study: 32903275

Group type: EXPERIMENTAL
Intervention: K3XF
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ProTaper Next
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: TF adaptive
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2Shape
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 36067479

Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (weekly and biweekly applications)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (including dHACA and standard of care)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 60
Study: 33617972

Group type: EXPERIMENTAL
Intervention: Supplement combination (Boswellia serrata extract 250 mg/day, pine bark extract 100 mg/day, methylsulfonylmethane 1,500 mg/day, curcumin 168 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Supplement combination
Number of subjects: 106
Study: 33484397

Group type: EXPERIMENTAL
Intervention: Parent-delivered therapy (5-week duration)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 73
Study: 33678535

Group type: COMPARATOR
Intervention: Natural menstrual cycle (placebo condition)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP condition)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low estradiol to progesterone ratio and testosterone concentrations
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low dfo
Number of subjects: 78
Study: 35194446

Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir (ATZ/RTV)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/RTV)
Number of subjects: 132
Study: 34996819

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (16 sessions over 12 weeks, plus 4 telephone follow-ups)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 35579951

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (three times a week, 20-35 min per session at 55%-70% of maximum heart rate)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 39
Study: 33675447

Group type: COMPARATOR
Intervention: Resting heart rate (RHR) > 100 beats per minute
Number of subjects: 1259485

Group type: COMPARATOR
Intervention: IQ above the highest tertile
Number of subjects: 1259485

Group type: COMPARATOR
Intervention: Physical fitness, BMI, blood pressure, or stress resilience
Number of subjects: 1259485

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for IQ
Number of subjects: 1259485

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for RHR
Number of subjects: 1259485
Study: 32696472

Group type: EXPERIMENTAL
Intervention: Online support
Number of subjects: 128

Group type: COMPARATOR
Intervention: Onsite support
Number of subjects: 128
Study: 35852564

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 33971152

Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine-PET/CT
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study: 32449063

Group type: EXPERIMENTAL
Intervention: Transcriptome assembly and annotation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Microsatellite marker development
Number of subjects: 90
Study: 34319998

Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulants (PAC)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No prophylactic anticoagulants (no PAC)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: S/P-albumin <20g/L
Number of subjects: 95

Group type: COMPARATOR
Intervention: S/P-albumin ≥20g/L
Number of subjects: 95
Study: 32303003

Group type: EXPERIMENTAL
Intervention: Locomotor skills
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Object control skills
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: BMI, object control skills, and engagement
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Motor engagement
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Self-perception
Number of subjects: 600
Study: 36007156

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control
Number of subjects: 338
Study: 33235154

Group type: EXPERIMENTAL
Intervention: Short-course induction chemotherapy (2 cycles of cisplatin 20 mg/m2 plus etoposide 40 or 100 mg/m2 for 5 days) followed by low-dose radiotherapy (dose: 2340 cGy) without a tumor bed boost
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy without a tumor bed boost
Number of subjects: 24
Study: 32975835

Group type: COMPARATOR
Intervention: 10 µg LSD
Number of subjects: 23

Group type: COMPARATOR
Intervention: 20 µg LSD
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5 µg LSD
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 µg, 10 µg, 20 µg LSD
Number of subjects: 23
Study: 33389959

Group type: EXPERIMENTAL
Intervention: Diabetic insulin users
Number of subjects: 60656

Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (male)
Number of subjects: 60656

Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (age 40-59)
Number of subjects: 60656

Group type: EXPERIMENTAL
Intervention: Diabetic insulin users (2 to 4 years of morbidity)
Number of subjects: 60656
Study: 32432990

Group type: EXPERIMENTAL
Intervention: Mindfulness-based strengths practice (MBSP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 32524991

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 265

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 265
Study: 34435738

Group type: EXPERIMENTAL
Intervention: Self-care education program (8-week duration)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 136
Study: 33946428

Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) bar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breakfast group (control)
Number of subjects: 0
Study: 32013276

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) on thoracic dorsal root ganglion (DRG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) on thoracic paravertebral nerve (PVN)
Number of subjects: 64
Study: 36454874

Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured with the Short Mood and Feelings Questionnaire (SMFQ), positive screen if scored ≥12
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Adolescents in South Africa
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Female adolescents
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Adolescents who reported ever having sex and being forced into sex
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Adolescents who self-reported to ever having had sex and used alcohol/drugs during their last sexual encounter
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Adolescents who reported using a condom during their last sexual encounter
Number of subjects: 2120
Study: 34294126

Group type: EXPERIMENTAL
Intervention: Online cultural experience named Ways of Being
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical museum website (the Ashmolean Museum)
Number of subjects: 0
Study: 33290971

Group type: EXPERIMENTAL
Intervention: Phytosterol capsules (1.5 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sunflower oil capsules (2 g/day)
Number of subjects: 31
Study: 32349789

Group type: EXPERIMENTAL
Intervention: CHW-delivered home-based screening
Number of subjects: 900

Group type: COMPARATOR
Intervention: Navigation to care by a CHW
Number of subjects: 900
Study: 35671976

Group type: EXPERIMENTAL
Intervention: Integral approach group (IA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: mHealth alone (Control group - CG)
Number of subjects: 80
Study: 33306985

Group type: EXPERIMENTAL
Intervention: G614 pseudovirus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBD monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convalescent sera from people infected with either form of the virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D614G mutation
Number of subjects: 0
Study: 35294543

Group type: EXPERIMENTAL
Intervention: Laser tonsillotomy under local anesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional tonsillectomy with general anesthesia
Number of subjects: 101
Study: 34365971

Group type: EXPERIMENTAL
Intervention: Provision of a clinical focus hypothesis
Number of subjects: 111

Group type: COMPARATOR
Intervention: No focus hypothesis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Overall detection of epileptogenic lesions
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Long-term epilepsy associated tumors
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Gliotic scar, hemosiderin or cavernoma
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hippocampal sclerosis or limbic encephalitis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Nodular heterotopia
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Focal cortical dysplasias
Number of subjects: 111
Study: 34560708

Group type: EXPERIMENTAL
Intervention: STEPS intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 32
Study: 33843366

Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) preoperative and postoperative assessment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Multi-Dimensional Voice Program analysis
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (20 randomly selected patients without vocal fold paresis or paralysis)
Number of subjects: 181
Study: 35672853

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 203

Group type: COMPARATOR
Intervention: Efavirenz-based ART
Number of subjects: 203
Study: 32529506

Group type: EXPERIMENTAL
Intervention: 4-week HIIT intervention (n=21)
Number of subjects: 41
Study: 35491320

Group type: COMPARATOR
Intervention: Standard information on side-effects (control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Standard information with additional information about CRCS (information)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Standard and additional information with a subsequent self‐affirmative text (information+SA)
Number of subjects: 160
Study: 34709363

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 312

Group type: COMPARATOR
Intervention: Aflibercept or Bevacizumab
Number of subjects: 312
Study: 35972446

Group type: EXPERIMENTAL
Intervention: Blimp balloon
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low-profile balloon
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Blimp balloon after LP balloon failure
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low-profile balloon after Blimp balloon failure
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Blimp balloon overall success after guide catheter extension
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low-profile balloon overall success after guide catheter extension
Number of subjects: 126
Study: 33507350

Group type: EXPERIMENTAL
Intervention: Scroll reconstruction
Number of subjects: 28

Group type: COMPARATOR
Intervention: No scroll reconstruction (Control)
Number of subjects: 28
Study: 33485377

Group type: EXPERIMENTAL
Intervention: Reasons for not smoking cigarettes (self-reported)
Number of subjects: 1559
Study: 35171823

Group type: EXPERIMENTAL
Intervention: Reduced ETTCP
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Unadjusted ETTCP
Number of subjects: 1671
Study: 34479573

Group type: EXPERIMENTAL
Intervention: gLiFE
Number of subjects: 309

Group type: COMPARATOR
Intervention: LiFE
Number of subjects: 309
Study: 32740819

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced videofluoroscopy (VFS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unenhanced 3-T MRI
Number of subjects: 21
Study: 33028566

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (20 mg/kg for 3 days, followed by 10 mg/kg for a further 7 days)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin
Number of subjects: 796

Group type: COMPARATOR
Intervention: Intravenous azithromycin and placebo
Number of subjects: 796
Study: 35652747

Group type: COMPARATOR
Intervention: Standard procedures
Number of subjects: 3465

Group type: EXPERIMENTAL
Intervention: Additive Holter electrocardiogram
Number of subjects: 3465
Study: 34969074

Group type: EXPERIMENTAL
Intervention: CGA admission avoidance hospital at home (HAH)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Admission to hospital
Number of subjects: 700
Study: 32936837

Group type: EXPERIMENTAL
Intervention: AMBER care bundle
Number of subjects: 38
Study: 35365148

Group type: EXPERIMENTAL
Intervention: Diet intake group (400 kcal)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Glucose intake group (75 g glucose)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 146
Study: 35610083

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention including nutrition education using a smartphone game, aerobic exercise, and cognitive behavioral therapy (CBT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual traditional nutritional education
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention
Number of subjects: 62
Study: 32046467

Group type: EXPERIMENTAL
Intervention: lncRNA and mRNA expression profiling
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Validation of expression levels
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Functional analysis of lncRNAs
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Functional analysis of mRNAs
Number of subjects: 2
Study: 34465443

Group type: EXPERIMENTAL
Intervention: 2020 San Francisco sugary drink warning label
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Control label ('Always read the Nutrition Facts Panel')
Number of subjects: 2160
Study: 33991353

Group type: EXPERIMENTAL
Intervention: Peanut bead‐based epitope assay (peanut BBEA)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Existing diagnostic tests for peanut allergy (including skin prick testing, peanut sIgE, and peanut component sIgE testing)
Number of subjects: 299
Study: 32443319

Group type: EXPERIMENTAL
Intervention: UVA/riboflavin cross-linking (0.1% riboflavin solution for 10 minutes)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Soaked in 0.1% riboflavin for 10 minutes (B2 group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (directly into corneal preservation solution)
Number of subjects: 49
Study: 35837807

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Natural course (NC)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in AIDP subtype
Number of subjects: 189

Group type: COMPARATOR
Intervention: Natural course (NC) in AIDP subtype
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in AMAN subtype
Number of subjects: 189

Group type: COMPARATOR
Intervention: Natural course (NC) in AMAN subtype
Number of subjects: 189
Study: 34531963

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Watchful waiting (control)
Number of subjects: 57
Study: 35909384

Group type: EXPERIMENTAL
Intervention: Awake-prone positioning (APP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional positioning interventions (Control)
Number of subjects: 82
Study: 33436336

Group type: EXPERIMENTAL
Intervention: Expander Prosthesis (EP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: DIEP flap
Number of subjects: 73
Study: 33222598

Group type: EXPERIMENTAL
Intervention: High Lp(a) group (≥60 mg/dL)
Number of subjects: 3943

Group type: COMPARATOR
Intervention: Low Lp(a) group (<60 mg/dL)
Number of subjects: 3943

Group type: EXPERIMENTAL
Intervention: Increasing quintiles of Lp(a)
Number of subjects: 3943
Study: 35970199

Group type: EXPERIMENTAL
Intervention: Placement of intrauterine device within 48 hours after abortion
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placement of intrauterine device at 2-4 weeks after abortion
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 34161899

Group type: EXPERIMENTAL
Intervention: Pediatric-onset Multiple Sclerosis (POMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Theory of Mind (ToM) tests
Number of subjects: 30

Group type: COMPARATOR
Intervention: ToM performance analysis by age of disease onset
Number of subjects: 30
Study: 36115963

Group type: EXPERIMENTAL
Intervention: TransformUs intervention, delivered by teachers with varying levels of implementation (Low < 33%, Moderate 33-67%, High > 67%).
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: TransformUs intervention, delivered by teachers.
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: TransformUs intervention, teachers' implementation level.
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: TransformUs intervention, overall program evaluation.
Number of subjects: 407
Study: 32781894

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation
Number of subjects: 603

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 603
Study: 34888612

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Esmolol (E)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study: 35953729

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study: 33638625

Group type: EXPERIMENTAL
Intervention: Fexofenadine/pseudoephedrine combination tablet (F/P)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fexofenadine (F)
Number of subjects: 24
Study: 32762736

Group type: EXPERIMENTAL
Intervention: Psychological skills training (PST)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both PST and MT
Number of subjects: 95
Study: 35793110

Group type: EXPERIMENTAL
Intervention: H‐FIRE ablation of all lesions identified with biopsy
Number of subjects: 109
Study: 33383198

Group type: EXPERIMENTAL
Intervention: Irrigation group (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonirrigation group (n=19)
Number of subjects: 40
Study: 32822600

Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 138
Study: 36114738

Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HVG; 5 sets/exercise)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Moderate-volume resistance training (MVG; 3 sets/exercise)
Number of subjects: 38
Study: 33509270

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with target mean arterial pressure 65 mmHg (MAP 65)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled hypotension with target mean arterial pressure 75 mmHg (MAP 75)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (MAP 65 and MAP 75)
Number of subjects: 40
Study: 32795925

Group type: EXPERIMENTAL
Intervention: 200 mg/d antofloxacin (AT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg/d antofloxacin (AT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg/d moxifloxacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33275787

Group type: EXPERIMENTAL
Intervention: Tele‐BA (behavioral activation tele-delivered by bachelor's‐level lay counselors)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Tele‐PST (problem-solving therapy tele-delivered by licensed clinicians)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Telephone support calls (attention control)
Number of subjects: 277
Study: 34526104

Group type: EXPERIMENTAL
Intervention: Kabasura Kudineer (KSK) 60 mL twice daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin C 60,000 IU daily and zinc 100 mg daily for 7 days (Control)
Number of subjects: 0
Study: 33599086

Group type: EXPERIMENTAL
Intervention: Warm humidified CO2 (WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard procedure (non-WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 10
Study: 33143704

Group type: EXPERIMENTAL
Intervention: Short regimen (9-11 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long regimen (20+ months)
Number of subjects: 0
Study: 34403493

Group type: EXPERIMENTAL
Intervention: Larger tracheal tubes (7.5-mm for men, 7.0-mm for women)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Smaller tracheal tubes (6.5-mm for men, 6.0-mm for women)
Number of subjects: 172
Study: 32986087

Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) consuming 2.66 (1.85) g/wk of gluten from age 4 months.
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Standard introduction group (SIG) consuming 0.49 (1.40) g/wk of gluten between ages 4 and 6 months.
Number of subjects: 1004
Study: 616026381

Group type: EXPERIMENTAL
Intervention: Bimatoprost-timolol fixed combination (BTFC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 39